Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Ratings Get Better


Dallas, Texas 03/20/2014 (FINANCIALSTRENDS) –  Northwest Biotherapeutics, Inc (NASDAQ:NWBO), a clinical-stage biopharmaceutical company developing immunotherapeutic options for cancer treatment, is bettering its rating from last week to this week. It should be noted that last week the company’s shares dipped drastically after receiving a downgrade from a research firm Oppenheimer. In light of concerns over its valuations, Oppenheimer downgraded Northwest Biotherapeutics’s shares to “perform” from “outperform”.

If you remember, last week the company’s stock rose by as much as 36 percent in wake of special approvals in Germany. Northwest Biotherapeutics announced that Germany has given an approval to sell the company’s brain cancer drug, DCVax-L, in the country. Also, in return, the company will be able to charge full money for the medications, and be reimbursed through sickness funds.

After receiving a special hospital exemption from Germany on its “experimental” drug, Northwest Biotherapeutics surged by a whopping 36 percent. Under the special permission, the company will be able to sell its cancer drug for five years in the country; and would also hold the right to further extend or renew the marketing rights after the term of five years get completed.

It is interesting to note that the final-stage study of DCVax-L is yet to be completed, but Germany’s approval does bring lot of cheer among the company’s investors. The drug is being tested in patients suffering from the most severe form of the disease, known as ‘Glioblastoma multiforme’.

On the other hand, initial data from DCVax-L’s late-stage trial was expected to come last month, but has not yet made available. This has definitely been a reason for concern.

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is expected to start selling its product in Germany in the next few months; and said it would also increase the production at its Leipzig facility.